RANI News and Press, Rani Therapeutics Holdings Inc. From 11/15/21

SAN JOSE, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quart...

Rani Therapeutics Holdings Inc. (NASDAQ:RANI) traded today at a new 52-week high of $36.00. This new high was reached on above average trading volume as 881,000 shares traded hands, while the average 30-day volume is approximately 65,000 shares. Rani Therapeutics Holdings Inc. (NASDAQ:RA...

SAN JOSE, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biolog...

SAN JOSE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (NASDAQ: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will participate in a fireside chat at th...

Rani Therapeutics Holdings Inc. (NASDAQ:RANI) traded at a new 52-week high today of $34.50. Approximately 881,000 shares have changed hands today, as compared to an average 30-day volume of 57,000 shares. Over the past year, Rani Therapeutics Holdings Inc. has traded in a range of $9.24 ...

Gainers: Merus (NASDAQ:MRUS) +36%, Nutriband (OTCQB:NTRB) +16%, Skylight Health (NASDAQ:SLHG) +16%, Rani Therapeutics (NASDAQ:RANI) +12%, Jupiter Wellness (NASDAQ:JUPW) +12%. Losers: Osmotica Pharmaceuticals (NASDAQ:OSMT) -38%, Prelude Therapeutics (NAS...

There's a good chance that someone you know (if not you personally) has a fear of syringes or injections. An estimated 50 million Americans share that fear, and a 2019 article published in the Journal of Advanced Nursing showed that 20% to 30% of all people between the ages of 20 and 40 ...

SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at the Cantor Fitzgerald Vi...

Gainers: FIXX +9.8%. DTIL +7.6%. REGI +5.3%. SPPI +5.2%. RANI +4.7%. Losers: EAR -51.2%. SYBX -8.9%. GRIN -6.4%. QRVO -6.4%. FA -5.0%. For further details see: FIXX, DTIL, EAR and SYBX among after hours movers

- IPO in July 2021 raised $84.3 million in gross proceeds - - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership team with key management and board of directors’ appointments - SAN JOSE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeuti...